Understandingthe pharmaceutical value chain
M. Aitken / Understanding the pharmaceutical value chain 57 Fig. 1. Costs incurred and value added in components of the pharmaceutical value chain. and bring new medicines to market. Due to the large financial investment involved, these medicines receive a period of market exclusivity. At the point this expires,
Download Understandingthe pharmaceutical value chain
Information
Domain:
Source:
Link to this page:
Documents from same domain
IFPMA Code of Practice
www.ifpma.orgThe IFPMA Code of Practice is a tangible example of the research-based pharmaceutical industry’s commitment to making a strong contribution to global public health while adhering to the highest standard of practice.
Code of Practice - ifpma.org
www.ifpma.orgOur Code of Practice was first drawn up in 1981, and it was the first one of its kind for any sector. Initially, correct information on the effects and side effects of medicines were at the core of the Code. Today, through periodic updates, expectations regarding compliance are …
T HE PHARMACEUTICAL FACTS AND INDUSTRY AND …
www.ifpma.orgFACTS AND. FIGURES 2017. This compendium of facts and figures relating to the pharmaceutical industry and global health aims to provide a snapshot of the work this industry undertakes today. This publication examines the most recent data on pharmaceutical innovation and
Introduction to Biosimilars & Regulatory Requirements
www.ifpma.org(Safety, ef fi cacy, immunogenicity) Reference Product Development Demonstrate safety, purity and potency Biosimilar Development Demonstrate biosimilarity to the reference product The inverted pyramid illustrates how the focus on certain aspects of product development changes
The Globalisation of the Pharmaceutical Industry Monograph
www.ifpma.orgPharmaceuticals Policy and Law 18 (2016) 1–4 1 DOI 10.3233/PPL-160427 IOS Press Editorial – The innovation and access to landscape Jose Luis Valverdea,∗ and Eduardo Pisanib aChair Jean Monnet of EU Law, Granada, Spain bInternational Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland
RESEARCH REPORT SEPTEMBER 2020 The Global Economic …
www.ifpma.orgprivate consumption, are the global pharmaceutical industry’s economic spillover effects. The present impact evaluation is based on industry level and utilizes the UN’s International Standard Industrial Classification of All Economic Activities (ISIC) Rev. 4. In it, class C21
Related documents
Investigating the impact of global stablecoins
www.bis.orgTechnological innovation is transforming the provision of financial services and products. Payment services, in particular, have seen significant change in recent years through the introduction of new ... serving as a means of payment and store of value, and they could potentially contribute to the ... functions-based regulatory approach, and ...
UNDERSTANDING SOCIAL IMPACT BONDS - OECD
www.oecd.orgWith this in mind and given its longstanding work in the field of social innovation and social entrepreneurship, the OECD LEED Programme has been tasked by the Ministry of , Employment, Labour ... are also known as Payment-for-Success bonds (USA) or Pay-for-Benefits bonds (Australia) (OECD, 2015; ... Based on this, the payment to the investor ...
Digital currencies and the future of the monetary system
www.bis.orgselling. Perhaps it is no surprise that we’ve seen a burst of digital innovation in payments, including new digital payment offerings by fintech startups, big techs and incumbents. 8 Many payment innovations build on improvements to underlying infrastructure s that have been many years in the making.